Ca2+ channel blockade prevents lysergic acid diethylamide-induced changes in dopamine and serotonin metabolism

European Journal of Pharmacology

Volumn 332, Issue 1, 1997, Pages 9-14

  Antkiewicz Michaluk, Lucyna ^a   Romańska, Irena ^a   Vetulani, Jerzy ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Biogenic amines; Brain; Ca2+ channel; Chronic treatment; LSD (lysergic acid diethylamide); Nifedipine

Indexed keywords

3 O METHYLDOPAMINE; 3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; BRAIN MONOAMINE; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; DOPAMINE; HOMOVANILLIC ACID; LYSERGIDE; NIFEDIPINE; SEROTONIN; SEROTONIN AGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DRUG ANTAGONISM; FRONTAL CORTEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MONOAMINE METABOLISM; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; ANIMAL; BRAIN; DRUG EFFECT; DRUG INTERACTION; HALLUCINATION; METABOLISM; VISUAL CORTEX; WISTAR RAT;

ANIMALS; BRAIN; CALCIUM CHANNEL BLOCKERS; DOPAMINE; DRUG INTERACTIONS; HALLUCINATIONS; INJECTIONS, INTRAPERITONEAL; LYSERGIC ACID DIETHYLAMIDE; MALE; NIFEDIPINE; NUCLEUS ACCUMBENS; RATS; RATS, WISTAR; SEROTONIN; SEROTONIN AGONISTS; VISUAL CORTEX;

EID: 0030612642     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01025-X     Document Type: Article

References (25)

1. Altura, B.T., Altura, B.M., 1981. Phencyclidine, lysergic acid diethylamide, and mescaline: Cerebral artery spasms and hallucinogenic activity. Science 212, 1051.
2. 2+ channels. Eur. J. Pharmacol. 294, 459.
3. Antkiewicz-Michaluk, L., Michaluk, J., Romańska, I., Vetulani, J., 1993. Reduction of morphine dependence and potentiation of analgesia by chronic co-administration of nifedipine. Psychopharmacology 111, 457.
4. Asaad, G., Shapiro, B., 1986. Hallucinations: Theoretical and clinical overview. Am. J. Psychiatry 143, 1088.
5. Bowers, M.B., 1977. Psychoses precipitated by psychotomimetic drugs. A follow-up study. Arch. Gen. Psychiatry 34, 832.
6. Freedman, D.X., 1984. LSD: The bridge from human to animal. In: Jacobs, B.L. (Eds.), Hallucinogens: Neurochemical, Behavioral and Clinical Perspectives. Raven Press, New York, NY, p. 203.
7. Friedman, A., Sienkiewicz, J., 1991. Central side effects of long-term treatment of Parkinson disease with levodopa preparations. Neurol. Neurochir. Pol. 25, 449.
8. Geyer, M.A., Brief, D.L., 1987. Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophr. Bull. 13, 643.
9. Glennon, R.A., Titeler, M., McKenney, J.D., 1984. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 35, 2505.
10. Grilly, D.M., 1989. Drugs and Human Behavior. Allyn and Bacon, Boston, MA.
11. Isbell, H., Belleville, R.E., Fraser, H.F., Wikler, A., Logan, C.R., 1956. Studies on lysergic acid diethylamide (LSD-25). 1. Effects in former morphine addicts and development of tolerance during chronic intoxication. Am. Arch. Neurol. Psychiatry 76, 468.
12. Jarvic, M., 1975. Drugs used in the treatment of psychiatric disorders. In: Goodman, L.S., Gilman, A. (Eds.), The Pharmacological Basis of Therapeutics. Collier Macmillan, London, p. 151.
13. Krebs, K.M., Geyer, M.A., 1994. Cross-tolerance studies of serotonin receptors involved in behavioral effects of LSD in rats. Psychopharmacology 113, 429.
14. Leikin, J.B., Krantz, A.J., Zell-Kanter, M., Barkin, R.L., Hryhorczuk, D.O., 1989. Clinical features and management of intoxication due to drugs. Med. Toxicol. Adverse Drug Exp. 4, 324.
15. Moskovitz, C., Moses, H., Klawans, H.L., 1978. Levodopa-induced psychosis: A kindling phenomenon. Am. J. Psychiatry 135, 669.
16. Nakamura, S., Fukuda, H., Hara, K., Fukuyama, H., Kameyama, M., 1988. Biochemical aspects of Parkinson-dementia complex. Eur. Neurol. 28 (Suppl. 1), 24.
17. Papac, D.I., Foltz, R.L., 1990. Measurement of lysergic acid diethylamide (LSD) in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. J. Anal. Toxicol. 14, 189.
18. 2+ currents in central 5-HT- containing neurons: 5-HT1A receptors may play a role in hallucinogenesis. J. Pharmacol. Exp. Ther. 269, 1160.
19. Pieri, L., Keller, H.H., Burkard, W., Da Prada, M., 1978. Effects of lisuride and LSD on cerebral monoamine systems and hallucinosis. Nature 272, 278.
20. Romano, A.G., Du, W., Harvey, J.A., 1994. Ethylenedioxyamphetamine: A selective effect on cortical content and turnover of 5-HT. Pharmacol. Biochem. Behav. 49, 599.
21. Schwartz, R.H., 1995. LSD. Its rise, fall and renewed popularity among high school students. Pediatr. Clin. North Am. 42, 403.
22. Seeman, P., 1987. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1, 133.
23. Watts, V.L., Lawder, C.P., Fox, D.R., Neve, K.A., Nichols, D.E., Mailman, R.B., 1995. LSD and structural analogs: Pharmacological evaluation at D1 dopamine receptors. Psychopharmacology 118, 401.
24. White, F.J., 1986. Comparative effects of LSD and lisuride: Clues to specific hallucinogenic drug action. Pharmacol. Biochem. Behav. 24, 365.
25. Zemlan, F.P., Hirschowitz, J., Sautter, F., Garver, D.L., 1986. Relationship of psychotic symptom clusters in schizophrenia to neuroleptic treatment and growth hormone response to apomorphine. Psychiatry Res. 18, 239.